

Lauren M Byrne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/79711111/publications.pdf>

Version: 2024-02-01

30
papers

1,097
citations

567281

15
h-index

752698

20
g-index

36
all docs

36
docs citations

36
times ranked

1306
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. <i>Lancet Neurology</i> , The, 2017, 16, 601-609. | 10.2 | 272 |
| 2 | Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease. <i>Science Translational Medicine</i> , 2018, 10, . | 12.4 | 134 |
| 3 | Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis. <i>Lancet Neurology</i> , The, 2020, 19, 502-512. | 10.2 | 122 |
| 4 | Neurofilament light protein in blood predicts regional atrophy in Huntington disease. <i>Neurology</i> , 2018, 90, e717-e723. | 1.1 | 65 |
| 5 | Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease. <i>Science Translational Medicine</i> , 2020, 12, . | 12.4 | 64 |
| 6 | Cerebrospinal Fluid Biomarkers for Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2016, 5, 1-13. | 1.9 | 60 |
| 7 | Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease. <i>Journal of Neurochemistry</i> , 2016, 139, 22-25. | 3.9 | 58 |
| 8 | Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's Disease. <i>PLoS ONE</i> , 2016, 11, e0163479. | 2.5 | 58 |
| 9 | Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay. <i>Journal of Huntington's Disease</i> , 2017, 6, 349-361. | 1.9 | 48 |
| 10 | Huntington's disease mice and human brain tissue exhibit increased G3BP1 granules and TDP43 mislocalization. <i>Journal of Clinical Investigation</i> , 2021, 131, . | 8.2 | 38 |
| 11 | Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease. <i>Journal of Neuroscience</i> , 2021, 41, 780-796. | 3.6 | 37 |
| 12 | Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease. <i>Scientific Reports</i> , 2018, 8, 4260. | 3.3 | 25 |
| 13 | Biofluid Biomarkers in Huntington's Disease. <i>Methods in Molecular Biology</i> , 2018, 1780, 329-396. | 0.9 | 21 |
| 14 | Characterizing White Matter in Huntington's Disease. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 52-60. | 1.5 | 20 |
| 15 | Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease. <i>Journal of Neurochemistry</i> , 2021, 158, 539-553. | 3.9 | 18 |
| 16 | A Remote Digital Monitoring Platform to Assess Cognitive and Motor Symptoms in Huntington Disease: Cross-sectional Validation Study. <i>Journal of Medical Internet Research</i> , 2022, 24, e32997. | 4.3 | 15 |
| 17 | Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington's disease. <i>Scientific Reports</i> , 2021, 11, 3481. | 3.3 | 12 |
| 18 | Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in Children. <i>Movement Disorders</i> , 2022, 37, 1526-1531. | 3.9 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease. PLoS ONE, 2020, 15, e0233820. | 2.5 | 8 |
| 20 | Cerebrospinal fluid flow dynamics in Huntington's disease evaluated by phase contrast MRI. European Journal of Neuroscience, 2019, 49, 1632-1639. | 2.6 | 5 |
| 21 | D4...Prediction of huntington's disease phenotype by cerebrospinal fluid biomarkers of inflammation and cell death. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A35.1-A35. | 1.9 | 0 |
| 22 | D10...Neurofilament light protein in blood predicts regional atrophy in huntington's disease. , 2018, , . | | 0 |
| 23 | D09...Parallel evaluation of mutant huntingtin and neurofilament light as biomarkers for huntington's disease: the hd-csf study. , 2018, , . | | 0 |
| 24 | F05...Biological and clinical characteristics of gene carriers far from predicted onset in the hd-yas study: a cross-sectional analysis. , 2021, , . | | 0 |
| 25 | E07...Cerebrospinal fluid flow dynamics in huntington's disease using phase contrast MRI: a pilot cross-sectional study. , 2018, , . | | 0 |
| 26 | D08...Neurofilament light protein in blood as a potential biomarker of neurodegeneration in huntington's disease: a retrospective cohort analysis. , 2018, , . | | 0 |
| 27 | Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease. , 2020, 15, e0233820. | | 0 |
| 28 | Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease. , 2020, 15, e0233820. | | 0 |
| 29 | Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease. , 2020, 15, e0233820. | | 0 |
| 30 | Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease. , 2020, 15, e0233820. | | 0 |